Steris PLC Form 4 insider transactions

Director Pierre Boulud was granted 367 Career Restricted Stock Units by STERIS plc on June 2, 2026.

STERIS plc insider John Adam Zangerle reports transactions involving ordinary shares, including vesting of restricted stock and tax withholdings.

Renato Tamaro, V.P. & Corporate Treasurer of STERIS plc, reported a transaction involving the withholding of 81 ordinary shares to cover tax obligations upon the vesting of restricted shares.

Lindsey McGowan, VP, Chf. Comp. & Quality Offc. of STERIS plc, reported transactions involving ordinary shares on June 1, 2026.

Cary L. Majors, SVP and President of Healthcare at STERIS plc, reported a series of transactions involving ordinary shares, including the vesting of restricted shares and the withholding of shares for tax purposes.

Julia Madsen, Sr. VP and GM of Life Sciences at STERIS plc, reported a transaction involving the withholding of shares for tax purposes and disclosed beneficial ownership details.

STERIS plc reports a transaction where SVP & GM, AST Kenneth E. Kohler disposed of 109 ordinary shares to cover tax withholding obligations upon vesting of restricted shares.

STERIS plc executive Mary Clare Fraser reports a transaction involving ordinary shares, with a portion withheld for tax obligations.

STERIS plc reports on executive stock vesting and tax withholding for President and CEO Daniel A. Carestio, detailing share transactions and beneficial ownership.

Karen L. Burton, Sr. Vice Pres., CFO of STERIS plc, reported transactions involving ordinary shares, including vesting and tax withholdings.

A STERIS plc director exercised stock options and subsequently sold an equivalent number of ordinary shares, adjusting their direct and indirect holdings.

STERIS plc's VP, Chief Compensation & Quality Officer, Lindsey McGowan, reported the acquisition of 798 restricted ordinary shares with a future vesting schedule.

STERIS plc Senior VP Julia Madsen exercised stock options and subsequently sold a portion of her shares on November 21, 2025.

STERIS plc's VP & Corporate Treasurer, Renato Tamaro, exercised stock options and subsequently sold a portion of his ordinary shares.

STERIS plc Senior VP John Zangerle exercised stock options and subsequently sold an equal number of ordinary shares on November 11, 2025.

STERIS plc President and CEO Daniel A. Carestio sold 159 ordinary shares for $241.82 each, executed under a pre-arranged 10b5-1 trading plan.

A STERIS plc Senior VP reported the vesting of restricted shares and subsequent tax withholding, a routine insider transaction.

STERIS plc's V.P. & Corporate Treasurer, Renato Tamaro, reported the vesting of restricted shares and the withholding of shares for tax obligations.

STERIS plc's SVP and President, Healthcare, Cary L. Majors, reported the vesting of restricted shares and the withholding of 303 shares for tax obligations.

STERIS plc Senior VP Julia Madsen reported the withholding of 52 ordinary shares to cover tax liabilities upon the vesting of restricted stock units on October 1, 2025.

STERIS plc's SVP & Chief HRO, Mary Clare Fraser, reported the vesting of restricted shares and the withholding of 207 shares for tax purposes.

STERIS plc CFO Karen L. Burton reported the vesting of restricted shares, tax-related share withholding, acquisition of new shares, and a grant of employee stock options.

STERIS plc CEO Daniel A. Carestio reported the vesting of 289 restricted shares and the withholding of 130 shares for tax purposes on October 1, 2025, a standard executive compensation event.

STERIS plc's VP & Corporate Treasurer, Renato Tamaro, exercised stock options and subsequently sold the acquired shares on August 20, 2025.

STERIS plc Director Richard C. Breeden exercised stock options to acquire 4,110 ordinary shares at $64.05 per share.

STERIS plc Director Mohsen Sohi reported the exercise of stock options and sale of shares, alongside new grants of equity awards.

STERIS plc Director Louis Shapiro acquired 975 fully vested Career Restricted Stock Units, aligning his interests with shareholders.

STERIS plc Director Nirav Shah was granted 1,407 nonqualified stock options and 487 career restricted stock units, both immediately vested.

STERIS plc Director Paul Edward Martin acquired 1,407 stock options and 487 career restricted stock units, enhancing his equity stake.

STERIS plc Director Christopher S. Holland acquired 975 fully vested Career Restricted Stock Units, which will settle six months after his board service ends.